Explore Fosun Pharma

  • Hot News

    Fosun Pharma Has Opened a New Era for Biosimilar in China Henlius Receives NMPA Approval for Its First Product HLX01

    Recently, HLX01 (rituximab injection), independently developed by Shanghai Henlius Biotech, Inc.(Henlius), Fosun Pharma’...

    Details
  • Hot News

    Conference Announcement | FOR A MALARIA-FREE WORLD Fosun Pharma at the 7th MIM Pan African Malaria Conference

    The 7th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference (Hereinafter referred to as MIM) will...

    Details
  • Hot News

    Strengthening Innovation and R&D, Deepening Internationalization Strategy

    Fosun Pharma Recorded Revenue of RMB18,534 1million in 2017, up by 26.69% YoY Net profit attributable to shareholders of the listed company after deduction of non-recurring profit or loss Recorded RMB2,346 million, up by 12.10% YoY R&D Investment amounted to RMB1,529 million, up by 38.26% YoY

    Details
  • Hot News

    100 Million Vials for Severe Malaria Treatments Supplied by Fosun Pharma, Estimated to Have Saved Over 20 Million Lives Worldwide

    Shanghai, China-November 5th, 2017-- Guilin Pharma, a member of Fosun Pharma (stock codes: 600196. SH; 02196, HK), ...

    Details

Quality System

13
GMP Certification

Innovation

Fosun Pharma Shares (A+H)

SH 600196

24.79

+0.52 +2.80%

2015-04-15 14:48:05

HK 02196

25.85

+0.52 +12.10%

2015-04-15 14:48:05

Refer to the Annual Financial Report

Recruitment

0
Recruitment Posts

Join Fosun Pharma